85 related articles for article (PubMed ID: 2131009)
21. Polymeric anticancer drugs with pH-controlled activation.
Ulbrich K; Subr V
Adv Drug Deliv Rev; 2004 Apr; 56(7):1023-50. PubMed ID: 15066758
[TBL] [Abstract][Full Text] [Related]
22. Poly(ethylene glycol) anticancer drug delivery systems.
Greenwald RB
P R Health Sci J; 2002 Jun; 21(2):113-21. PubMed ID: 12166021
[No Abstract] [Full Text] [Related]
23. Supramolecular drug-delivery systems based on polymeric core-shell architectures.
Haag R
Angew Chem Int Ed Engl; 2004 Jan; 43(3):278-82. PubMed ID: 14705079
[No Abstract] [Full Text] [Related]
24. Magnetically modulated therapeutic systems.
Häfeli UO
Int J Pharm; 2004 Jun; 277(1-2):19-24. PubMed ID: 15158965
[TBL] [Abstract][Full Text] [Related]
25. A chemical adaptor system designed to link a tumor-targeting device with a prodrug and an enzymatic trigger.
Gopin A; Pessah N; Shamis M; Rader C; Shabat D
Angew Chem Int Ed Engl; 2003 Jan; 42(3):327-32. PubMed ID: 12548691
[No Abstract] [Full Text] [Related]
26. Polymer-protein and polymer-drug conjugates in cancer therapy.
Thanou M; Duncan R
Curr Opin Investig Drugs; 2003 Jun; 4(6):701-9. PubMed ID: 12901229
[TBL] [Abstract][Full Text] [Related]
27. Anticancer drug delivery with nanoparticles.
Conti M; Tazzari V; Baccini C; Pertici G; Serino LP; De Giorgi U
In Vivo; 2006; 20(6A):697-701. PubMed ID: 17203748
[TBL] [Abstract][Full Text] [Related]
28. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect.
Maeda H; Bharate GY; Daruwalla J
Eur J Pharm Biopharm; 2009 Mar; 71(3):409-19. PubMed ID: 19070661
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and biological evaluation of novel taxoids designed for targeted delivery to tumors.
Baloglu E; Miller ML; Roller EE; Cavanagh EE; Leece BA; Goldmacher VS; Chari RV
Bioorg Med Chem Lett; 2004 Dec; 14(23):5885-8. PubMed ID: 15501062
[TBL] [Abstract][Full Text] [Related]
30. [Polyplex nanomicelles for drug delivery system].
Itaka K
Rinsho Ketsueki; 2008 May; 49(5):287-93. PubMed ID: 18572804
[No Abstract] [Full Text] [Related]
31. [Research progress on application of drug nano-carriers].
Wen T; Jia T; Wang YM; Luo GA
Yao Xue Xue Bao; 2003 Mar; 38(3):236-40. PubMed ID: 12830725
[No Abstract] [Full Text] [Related]
32. Nanomedicine and drug delivery.
Wei C; Wei W; Morris M; Kondo E; Gorbounov M; Tomalia DA
Med Clin North Am; 2007 Sep; 91(5):863-70. PubMed ID: 17826106
[TBL] [Abstract][Full Text] [Related]
33. Monoclonal antibody administration. Current clinical pharmacokinetic status and future trends.
Begent RH; Pedley RB
Clin Pharmacokinet; 1992 Aug; 23(2):85-9. PubMed ID: 1511531
[No Abstract] [Full Text] [Related]
34. Calcium phosphate nanocomposite particles: a safer and more effective alternative to conventional chemotherapy?
Altinoğlu EI; Adair JH
Future Oncol; 2009 Apr; 5(3):279-81. PubMed ID: 19374533
[No Abstract] [Full Text] [Related]
35. Improved immunotoxins with novel functional elements.
Hetzel C; Bachran C; Tur MK; Fuchs H; Stöcker M
Curr Pharm Des; 2009; 15(23):2700-11. PubMed ID: 19689340
[TBL] [Abstract][Full Text] [Related]
36. Clinical experience of targeted therapy.
Eichler HG
Biotherapy; 1991; 3(1):77-85. PubMed ID: 2009216
[TBL] [Abstract][Full Text] [Related]
37. Targeted toxins in pain.
Wiley RG; Lappi DA
Adv Drug Deliv Rev; 2003 Aug; 55(8):1043-54. PubMed ID: 12935943
[TBL] [Abstract][Full Text] [Related]
38. Targeted therapy in the macro mode.
Winn RJ
J Natl Compr Canc Netw; 2005 May; 3(3):235-6. PubMed ID: 16001999
[No Abstract] [Full Text] [Related]
39. Drug-immunoglobulin conjugates as targeted therapeutic systems.
Mitra AK; Ghosh MK
Targeted Diagn Ther; 1990; 3():141-87. PubMed ID: 2131009
[No Abstract] [Full Text] [Related]
40. Immunoconjugates in drug delivery systems.
Cannon JB; Hui HW
Targeted Diagn Ther; 1990; 3():121-39. PubMed ID: 2131008
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
